Veritas Genetics launch their first genetic test in an effort to revolutionize the testing industry.

“We believe that everyone has the right to actionable genetic information that can lead to early detection and prevention.” Those are the words that great visitors when they land on the Veritas Genetics website. This month has seen that belief manifested into the company’s very first genetic test, myBRCA.

So what’s different to the other tests out there? Veritas Genetics are making a big effort to put you in control, but support you along the way. You request the test, they get your doctor’s approval, results are shared with you and your doctor. Should you require it, you also have access to genetic counseling throughout the whole process. It shouldn’t go without saying that myBRCA is performed at Veritas’s own CLIA certified laboratory.

The cost of myBRCA is also driving at making information accessible at a very competitive $199 per test. Better yet, for each test purchased, Veritas Genetics are donating an additional test to advocacy organizations for distribution to women in financial need.

“Our mission goes well beyond a single genetic test,” adds Dr. Estep, founder and Chief Scientific Officer of Veritas and Director of Gerontology of the Personal Genome Project at Harvard Medical School. “We are building Veritas to contribute increasingly large amounts of data to public databases, advancing our collective understanding of disease incidence and progression, and ultimately accelerating progress in prevention, early detection, and treatment of diseases.”

“As a society, we have the opportunity and the responsibility to remove barriers to genetic testing that can lead to disease prevention and early detection,” says Mirza Cifric, Veritas Genetics’ Chief Executive Officer. “The true potential of personalized medicine will only be realized when we expand access to include all who can benefit.  And, importantly, it is critical to deliver this potentially life-changing information responsibly.”

As well as making information more accessible to consumers, the organization is also very keen to help the scientific community. They have joined FreeTheData, the Global Alliance for Genetics and Health’s BRCA Challenge, and will continue to contribute to the ClinVar database.

Direct-To-Consumer testing companies are very often seen as ‘the bad guys’ or ‘irresponsible’. In principle, Veritas seem to tick a lot of the right boxes. Whether or not they succeed in significantly disrupting the genetic testing industry remains to be seen. If anything, it seems like a lot of thought and genuine good intention is behind the project that will hopefully help a lot of women.